Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid, Caroline Robert, Adil Daud, et al.
Molecular Cancer Therapeutics|April 2, 2020
Biophysical and Immunological Characterization and <i>In Vivo</i> Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody PembrolizumabBeth Hutchins, Gary C Starling, Mark A McCoy, et al.
JAMA|April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.
Archives of Neurology|February 16, 2011
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 yearPetra Kaufmann, Michael P McDermott, Basil T Darras, et al.
Epilepsia|September 13, 2025
Quality of life over time after new onset refractory status epilepticusMatthew D Gruen, Margaret T Gopaul, Anthony D Jimenez, et al.
Nature Genetics|April 6, 2010
Discovery of common Asian copy number variants using integrated high-resolution array CGH and massively parallel DNA sequencingHansoo Park, Jong-Il Kim, Young Seok Ju, et al.
JAMA Neurology|April 27, 2026
Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status EpilepticusStefano Meletti, Aurelie Hanin, Giada Giovannini, et al.
Cancer Immunology Research|October 18, 2017
A Blueprint to Advance Colorectal Cancer ImmunotherapiesDung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, et al.
Epilepsia|June 26, 2026
Acute and Long-Term EEG and seizure characteristics in new onset refractory status epilepticus (NORSE)Kia Gilani, Aurélie Hanin, Nicolas Gaspard, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Pageof 9